Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-015703
Filing Date
2023-05-04
Accepted
2023-05-04 16:05:10
Documents
70
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q avtx-20230331.htm   iXBRL 10-Q 997177
2 EX-31.1 ex-3112023.htm EX-31.1 10634
3 EX-31.2 ex-3122023.htm EX-31.2 10420
4 EX-32.1 ex-3212023.htm EX-32.1 11181
10 GRAPHIC avtx-20230331_g1.jpg GRAPHIC 520109
  Complete submission text file 0001628280-23-015703.txt   7255219

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230331.xsd EX-101.SCH 54212
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avtx-20230331_cal.xml EX-101.CAL 60563
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20230331_def.xml EX-101.DEF 301686
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230331_lab.xml EX-101.LAB 642213
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230331_pre.xml EX-101.PRE 422973
64 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230331_htm.xml XML 855896
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37590 | Film No.: 23888565
SIC: 2834 Pharmaceutical Preparations